Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
Blauvelt, Andrew, Papp, Kim A., Griffiths, Christopher E.M., Randazzo, Bruce, Wasfi, Yasmine, Shen, Yaung-Kaung, Li, Shu, Kimball, Alexa B.Volume:
76
Language:
english
Journal:
Journal of the American Academy of Dermatology
DOI:
10.1016/j.jaad.2016.11.041
Date:
March, 2017
File:
PDF, 633 KB
english, 2017